Topical Capsaicin for the Treatment of Neuropathic Pain

Author(s): Adiba Sultana, Rajeev K. Singla, Xuefei He, Yan Sun, Md. Shahin Alam, Bairong Shen*

Journal Name: Current Drug Metabolism

Volume 22 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Neuropathic pain (NP) is an egregious problem worldwide. Due to the side-effects of oral drugs, drugs delivered directly to the affected area of pain are preferred.

Objective: Capsaicin, a chemical compound isolated from chili peppers, is used as an analgesic in topical ointments and dermal patches to alleviate pain. Objective of the study is to review the application and functionality of topical capsaicin in treatment of neuropathic pain.

Data sources: To systematically review capsaicin’s functions on NP, we retrieved articles from the PubMed database published in the last ten years.

Study eligibility criteria: The inclusion criteria were capsaicin and the use of capsaicin for the treatment of NP; on the other hand, articles were excluded according to the mentioned criteria such as abstracts, articles written in any language other than English, incomplete articles, and conference papers.

Participants and interventions: Out of 265 articles, 108 articles were selected after filtering through the inclusion and exclusion criteria. The data and knowledge currently existing for capsaicin treatment in NP are summarized.

Results: This review indicates that capsaicin effectively improves NP treatment without affecting the motor and large nerve fibres involved in sensory function. Transient receptor potential channel vanilloid type 1 (TRPV1) is the capsaicin receptor expressed in central and peripheral terminals of a sensitive primary nerve cell.

Conclusions and implications of key findings: Topical capsaicin has a sensible safety profile and is effective in reducing NP. Therefore, studies over the last decade suggest that capsaicin might be a potential drug for NP treatment.

Keywords: Neuropathic pain, neuromodulation, analgesic agent, natural products, TRPV1, capsaicin.

[1]
Bouhassira, D. Neuropathic pain: Definition, assessment and epidemiology. Rev. Neurol. (Paris), 2019, 175(1-2), 16-25.
[http://dx.doi.org/10.1016/j.neurol.2018.09.016] [PMID: 30385075]
[2]
Colloca, L.; Ludman, T.; Bouhassira, D.; Baron, R.; Dickenson, A.H.; Yarnitsky, D.; Freeman, R.; Truini, A.; Attal, N.; Finnerup, N.B.; Eccleston, C.; Kalso, E.; Bennett, D.L.; Dworkin, R.H.; Raja, S.N. Neuropathic pain. Nat. Rev. Dis. Primers, 2017, 3, 17002.
[http://dx.doi.org/10.1038/nrdp.2017.2] [PMID: 28205574]
[3]
Jensen, T.S.; Baron, R.; Haanpää, M.; Kalso, E.; Loeser, J.D.; Rice, A.S.; Treede, R.D. A new definition of neuropathic pain. Pain, 2011, 152(10), 2204-2205.
[http://dx.doi.org/10.1016/j.pain.2011.06.017] [PMID: 21764514]
[4]
Finnerup, N.B.; Haroutounian, S.; Kamerman, P.; Baron, R.; Bennett, D.L.; Bouhassira, D.; Cruccu, G.; Freeman, R.; Hansson, P.; Nurmikko, T.; Raja, S.N.; Rice, A.S.; Serra, J.; Smith, B.H.; Treede, R.D.; Jensen, T.S. Neuropathic pain: an updated grading system for research and clinical practice. Pain, 2016, 157(8), 1599-1606.
[http://dx.doi.org/10.1097/j.pain.0000000000000492] [PMID: 27115670]
[5]
Prudhomme, M.; Legras, A.; Delorme, C.; Lansaman, T.; Lanteri-Minet, M.; Medioni, J.; Navez, M.; Perrot, S.; Pickering, G.; Serrie, A.; Viel, E. Management of neuropathic pain induced by surgery: review of the literature by a group of experts specialized in pain management, anesthesia and surgery. J. Visc. Surg., 2020, 157(1), 43-52.
[http://dx.doi.org/10.1016/j.jviscsurg.2019.09.004] [PMID: 31668838]
[6]
Blanton, H.L.; Brelsfoard, J.; DeTurk, N.; Pruitt, K.; Narasimhan, M.; Morgan, D.J.; Guindon, J. Cannabinoids: current and future options to treat chronic and chemotherapy-induced neuropathic pain. Drugs, 2019, 79(9), 969-995.
[http://dx.doi.org/10.1007/s40265-019-01132-x] [PMID: 31127530]
[7]
Yang, X.D.; Fang, P.F.; Xiang, D.X.; Yang, Y.Y. Topical treatments for diabetic neuropathic pain. Exp. Ther. Med., 2019, 17(3), 1963-1976.
[PMID: 30783472]
[8]
Thapa, P.; Euasobhon, P. Chronic postsurgical pain: current evidence for prevention and management. Korean J. Pain, 2018, 31(3), 155-173.
[http://dx.doi.org/10.3344/kjp.2018.31.3.155] [PMID: 30013730]
[9]
Knezevic, N.N.; Tverdohleb, T.; Nikibin, F.; Knezevic, I.; Candido, K.D. Management of chronic neuropathic pain with single and compounded topical analgesics. Pain Manag, 2017, 7(6), 537-558.
[http://dx.doi.org/10.2217/pmt-2017-0020] [PMID: 29125423]
[10]
Larsson, I.M.; Ahm Sørensen, J.; Bille, C. The post-mastectomy pain syndrome-a systematic review of the treatment modalities. Breast J., 2017, 23(3), 338-343.
[http://dx.doi.org/10.1111/tbj.12739] [PMID: 28133848]
[11]
Hagen, E.M.; Rekand, T. Management of neuropathic pain associated with spinal cord injury. Pain Ther., 2015, 4(1), 51-65.
[http://dx.doi.org/10.1007/s40122-015-0033-y] [PMID: 25744501]
[12]
Smith, H.S.; Argoff, C.E. Pharmacological treatment of diabetic neuropathic pain. Drugs, 2011, 71(5), 557-589.
[http://dx.doi.org/10.2165/11588940-000000000-00000] [PMID: 21443281]
[13]
Rosenberger, D.C.; Blechschmidt, V.; Timmerman, H.; Wolff, A.; Treede, R.D. Challenges of neuropathic pain: focus on diabetic neuropathy. J. Neural Transm. (Vienna), 2020, 127(4), 589-624.
[http://dx.doi.org/10.1007/s00702-020-02145-7] [PMID: 32036431]
[14]
Bouhassira, D.; Letanoux, M.; Hartemann, A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoS One, 2013, 8(9)
[http://dx.doi.org/10.1371/journal.pone.0074195] [PMID: 24058527]
[15]
Jensen, M.P.; Chodroff, M.J.; Dworkin, R.H. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology, 2007, 68(15), 1178-1182.
[http://dx.doi.org/10.1212/01.wnl.0000259085.61898.9e] [PMID: 17420400]
[16]
Siddall, P.J.; McClelland, J.M.; Rutkowski, S.B.; Cousins, M.J. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain, 2003, 103(3), 249-257.
[http://dx.doi.org/10.1016/S0304-3959(02)00452-9] [PMID: 12791431]
[17]
Solaro, C.; Brichetto, G.; Amato, M.P.; Cocco, E.; Colombo, B.; D’Aleo, G.; Gasperini, C.; Ghezzi, A.; Martinelli, V.; Milanese, C.; Patti, F.; Trojano, M.; Verdun, E.; Mancardi, G.L.; Pa, I.M.S.S.G. PaIMS Study Group. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology, 2004, 63(5), 919-921.
[http://dx.doi.org/10.1212/01.WNL.0000137047.85868.D6] [PMID: 15365151]
[18]
Klit, H.; Finnerup, N.B.; Andersen, G.; Jensen, T.S. Central poststroke pain: a population-based study. Pain, 2011, 152(4), 818-824.
[http://dx.doi.org/10.1016/j.pain.2010.12.030] [PMID: 21272999]
[19]
Rayment, C.; Hjermstad, M.J.; Aass, N.; Kaasa, S.; Caraceni, A.; Strasser, F.; Heitzer, E.; Fainsinger, R.; Bennett, M.I. European Palliative Care Research Collaborative (EPCRC). Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat. Med., 2013, 27(8), 714-721.
[http://dx.doi.org/10.1177/0269216312464408] [PMID: 23175513]
[20]
Bennett, M.I.; Rayment, C.; Hjermstad, M.; Aass, N.; Caraceni, A.; Kaasa, S. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain, 2012, 153(2), 359-365.
[http://dx.doi.org/10.1016/j.pain.2011.10.028] [PMID: 22115921]
[21]
Gaskin, D.J.; Richard, P. The economic costs of pain in the United States. J. Pain, 2012, 13(8), 715-724.
[http://dx.doi.org/10.1016/j.jpain.2012.03.009] [PMID: 22607834]
[22]
Christelis, N. Neuropathy, Neuropathic Pain, and Painful Peripheral Neuropathy: Many Kinds, Causes, and Treatments; The International Neuromodulation Society, 2017.
[23]
Filimon, C. [Various considerations on the results of enterocystoplasty]. J. Urol. Nephrol. (Paris), 1970, 76(1), 79-89.
[PMID: 5439125]
[24]
Cheung, C.W.; Choi, S.W.; Wong, S.S.C.; Lee, Y.; Irwin, M.G. Changes in prevalence, outcomes, and help-seeking behavior of chronic pain in an aging population over the last decade. Pain Pract., 2017, 17(5), 643-654.
[http://dx.doi.org/10.1111/papr.12496] [PMID: 27735140]
[25]
Cavalli, E.; Mammana, S.; Nicoletti, F.; Bramanti, P.; Mazzon, E. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int. J. Immunopathol. Pharmacol., 2019, 33
[http://dx.doi.org/10.1177/2058738419838383] [PMID: 30900486]
[26]
Lim, E.Y.; Kim, Y.T. Food-derived natural compounds for pain relief in neuropathic pain. BioMed Res. Int., 2016, 2016
[http://dx.doi.org/10.1155/2016/7917528] [PMID: 27891521]
[27]
Harvey, A.L.; Edrada-Ebel, R.; Quinn, R.J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov., 2015, 14(2), 111-129.
[http://dx.doi.org/10.1038/nrd4510] [PMID: 25614221]
[28]
Chapa-Oliver, A.M.; Mejía-Teniente, L. Capsaicin: From Plants to a Cancer-Suppressing Agent. Molecules, 2016, 21(8), E931.
[http://dx.doi.org/10.3390/molecules21080931] [PMID: 27472308]
[29]
Basith, S.; Cui, M.; Hong, S.; Choi, S. Harnessing the therapeutic potential of capsaicin and its analogues in pain and other diseases. Molecules, 2016, 21(8), E966.
[http://dx.doi.org/10.3390/molecules21080966] [PMID: 27455231]
[30]
Fattori, V.; Hohmann, M.S.; Rossaneis, A.C.; Pinho-Ribeiro, F.A.; Verri, W.A. Capsaicin: current understanding of its mechanisms and therapy of pain and other pre-clinical and clinical uses. Molecules, 2016, 21(7), E844.
[http://dx.doi.org/10.3390/molecules21070844] [PMID: 27367653]
[31]
Tanrıkulu-Küçük, S.; Başaran-Küçükgergin, C.; Seyithanoğlu, M.; Doğru-Abbasoğlu, S.; Koçak, H.; Beyhan-Özdaş, Ş.; Öner-İyidoğan, Y. Effect of dietary curcumin and capsaicin on testicular and hepatic oxidant-antioxidant status in rats fed a high-fat diet. Appl. Physiol. Nutr. Metab., 2019, 44(7), 774-782.
[http://dx.doi.org/10.1139/apnm-2018-0622] [PMID: 30605349]
[32]
Ghiasi, Z.; Esmaeli, F.; Aghajani, M.; Ghazi-Khansari, M.; Faramarzi, M.A.; Amani, A. Enhancing analgesic and anti-inflammatory effects of capsaicin when loaded into olive oil nanoemulsion: an in vivo study. Int. J. Pharm., 2019, 559, 341-347.
[http://dx.doi.org/10.1016/j.ijpharm.2019.01.043] [PMID: 30710660]
[33]
Payab, M.; Hasani-Ranjbar, S.; Baeeri, M.; Rahimifard, M.; Arjmand, B.; Haghi-Aminjan, H.; Abdollahi, M.; Larijani, B. Development of a novel anti-obesity compound with inhibiting properties on the lipid accumulation in 3T3-L1 adipocytes. Iran. Biomed. J., 2020, 24(3), 155-63.
[PMID: 31952433]
[34]
Zhang, S.; Wang, D.; Huang, J.; Hu, Y.; Xu, Y. Application of capsaicin as a potential new therapeutic drug in human cancers. J. Clin. Pharm. Ther., 2020, 45(1), 16-28.
[http://dx.doi.org/10.1111/jcpt.13039] [PMID: 31545523]
[35]
Blair, H.A. Capsaicin 8% dermal patch: a review in peripheral neuropathic pain. Drugs, 2018, 78(14), 1489-1500.
[http://dx.doi.org/10.1007/s40265-018-0982-7] [PMID: 30251173]
[36]
Laklouk, M.; Baranidharan, G. Profile of the capsaicin 8% patch for the management of neuropathic pain associated with postherpetic neuralgia: safety, efficacy, and patient acceptability. Patient Prefer. Adherence, 2016, 10, 1913-1918.
[http://dx.doi.org/10.2147/PPA.S76506] [PMID: 27703336]
[37]
Schumacher, M.; Pasvankas, G. Topical capsaicin formulations in the management of neuropathic pain. Prog. Drug Res., 2014, 68, 105-128.
[http://dx.doi.org/10.1007/978-3-0348-0828-6_4] [PMID: 24941666]
[38]
Jorge, L.L.; Feres, C.C.; Teles, V.E. Topical preparations for pain relief: efficacy and patient adherence. J. Pain Res., 2010, 4, 11-24.
[http://dx.doi.org/10.2147/JPR.S9492] [PMID: 21386951]
[39]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med., 2009, 6(7), e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[40]
Forstenpointner, J.; Naleschinski, D.; Wasner, G.; Hüllemann, P.; Binder, A.; Baron, R. Sensitized vasoactive C-nociceptors: key fibers in peripheral neuropathic pain. Pain Rep., 2019, 4(1), e709.
[http://dx.doi.org/10.1097/PR9.0000000000000709] [PMID: 30801047]
[41]
Perrot, S.; Lantéri-Minet, M. Patients’ global impression of change in the management of peripheral neuropathic pain: clinical relevance and correlations in daily practice. Eur. J. Pain, 2019, 23(6), 1117-1128.
[http://dx.doi.org/10.1002/ejp.1378] [PMID: 30793414]
[42]
Lantéri-Minet, M.; Perrot, S. QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France. Curr. Med. Res. Opin., 2019, 35(3), 417-426.
[http://dx.doi.org/10.1080/03007995.2018.1558850] [PMID: 30550354]
[43]
Wang, C.; Gu, L.; Ruan, Y.; Gegen, T.; Yu, L.; Zhu, C.; Yang, Y.; Zhou, Y.; Yu, G.; Tang, Z. Pirt together with TRPV1 is involved in the regulation of neuropathic pain. Neural Plast., 2018, 2018
[http://dx.doi.org/10.1155/2018/4861491] [PMID: 29808083]
[44]
Hansson, P.; Jensen, T.S.; Kvarstein, G.; Strömberg, M. Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. Eur. J. Pain, 2018, 22(5), 941-950.
[http://dx.doi.org/10.1002/ejp.1180] [PMID: 29388284]
[45]
Mankowski, C.; Poole, C.D.; Ernault, E.; Thomas, R.; Berni, E.; Currie, C.J.; Treadwell, C.; Calvo, J.I.; Plastira, C.; Zafeiropoulou, E.; Odeyemi, I. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol., 2017, 17(1), 80.
[http://dx.doi.org/10.1186/s12883-017-0836-z] [PMID: 28431564]
[46]
Kern, K.U.; Nowack, W.; Poole, C. Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary? Pain Pract., 2014, 14(2), E42-E50.
[http://dx.doi.org/10.1111/papr.12143] [PMID: 24289500]
[47]
Shenoy, R.; Roberts, K.; Papadaki, A.; McRobbie, D.; Timmers, M.; Meert, T.; Anand, P. Functional MRI brain imaging studies using the Contact Heat Evoked Potential Stimulator (CHEPS) in a human volunteer topical capsaicin pain model. J. Pain Res., 2011, 4, 365-371.
[http://dx.doi.org/10.2147/JPR.S24810] [PMID: 22090805]
[48]
Gálvez, R.; Navez, M.L.; Moyle, G.; Maihöfner, C.; Stoker, M.; Ernault, E.; Nurmikko, T.J.; Attal, N. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain: a 52-week, open-label, single-arm, safety study. Clin. J. Pain, 2017, 33(10), 921-931.
[http://dx.doi.org/10.1097/AJP.0000000000000473] [PMID: 28872473]
[49]
Mou, J.; Paillard, F.; Turnbull, B.; Trudeau, J.; Stoker, M.; Katz, N.P. Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. Clin. J. Pain, 2014, 30(4), 286-294.
[http://dx.doi.org/10.1097/AJP.0b013e31829a4ced] [PMID: 23765045]
[50]
Mou, J.; Paillard, F.; Turnbull, B.; Trudeau, J.; Stoker, M.; Katz, N.P. Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain, 2013, 154(9), 1632-1639.
[http://dx.doi.org/10.1016/j.pain.2013.04.044] [PMID: 23707278]
[51]
Derry, S.; Sven-Rice, A.; Cole, P.; Tan, T.; Moore, R.A. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2013, (2)
[http://dx.doi.org/10.1002/14651858.CD007393.pub3] [PMID: 23450576]
[52]
Treede, R.D.; Wagner, T.; Kern, K.U.; Husstedt, I.W.; Arendt, G.; Birklein, F.; Cegla, T.; Freynhagen, R.; Gockel, H.H.; Heskamp, M.L.; Jager, H.; Joppich, R.; Maier, C.; Leffler, A.; Nagelein, H.H.; Rolke, R.; Seddigh, S.; Sommer, C.; Stander, S.; Wasner, G.; Baron, R. Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Curr. Med. Res. Opin., 2013, 29(5), 527-538.
[http://dx.doi.org/10.1185/03007995.2013.781019] [PMID: 23444968]
[53]
Hall, G.C.; Morant, S.V.; Carroll, D.; Gabriel, Z.L.; McQuay, H.J. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Fam. Pract., 2013, 14, 28.
[http://dx.doi.org/10.1186/1471-2296-14-28] [PMID: 23442783]
[54]
Webster, L.R.; Peppin, J.F.; Murphy, F.T.; Tobias, J.K.; Vanhove, G.F. Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. J. Pain Res., 2012, 5, 7-13.
[http://dx.doi.org/10.2147/JPR.S25272] [PMID: 22328830]
[55]
Peppin, J.F.; Majors, K.; Webster, L.R.; Simpson, D.M.; Tobias, J.K.; Vanhove, G.F. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J. Pain Res., 2011, 4, 385-392.
[http://dx.doi.org/10.2147/JPR.S22954] [PMID: 22247621]
[56]
Webster, L.R.; Peppin, J.F.; Murphy, F.T.; Lu, B.; Tobias, J.K.; Vanhove, G.F. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Res. Clin. Pract., 2011, 93(2), 187-197.
[http://dx.doi.org/10.1016/j.diabres.2011.04.010] [PMID: 21612836]
[57]
Zis, P.; Apsokardos, A.; Isaia, C.; Sykioti, P.; Vadalouca, A. Posttraumatic and postsurgical neuropathic pain responsive to treatment with capsaicin 8% topical patch. Pain Physician, 2014, 17(2), E213-E218.
[PMID: 24658488]
[58]
Raber, J.M.; Reichelt, D.; Grüneberg-Oelker, U.; Philipp, K.; Stubbe- Dräger, B.; Husstedt, I.W. Capsaicin 8 % as a cutaneous patch (Qutenza™): analgesic effect on patients with peripheral neuropathic pain. Acta Neurol. Belg., 2015, 115(3), 335-343.
[http://dx.doi.org/10.1007/s13760-014-0395-7] [PMID: 25421590]
[59]
Zis, P.; Bernali, N.; Argira, E.; Siafaka, I.; Vadalouka, A. Effectiveness and impact of capsaicin 8% patch on quality of life in patients with lumbosacral pain: an open-label study. Pain Physician, 2016, 19(7), E1049-E1053.
[PMID: 27676676]
[60]
Levesque, A.; Riant, T.; Labat, J.J.; Ploteau, S. Use of high-concentration capsaicin patch for the treatment of pelvic pain: observational study of 60 inpatients. Pain Physician, 2017, 20(1), E161-E167.
[http://dx.doi.org/10.36076/2017.1.E161] [PMID: 28072808]
[61]
van Nooten, F.; Treur, M.; Pantiri, K.; Stoker, M.; Charokopou, M. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheralneuropathy: a systematic literature review and network meta-analysis. Clin. Ther., 2017, 39(4), 787-803.
[62]
Tajti, J.; Szok, D.; Majláth, Z.; Csáti, A.; Petrovics-Balog, A.; Vécsei, L. Alleviation of pain in painful diabetic neuropathy. Expert Opin. Drug Metab. Toxicol., 2016, 12(7), 753-764.
[http://dx.doi.org/10.1080/17425255.2016.1184648] [PMID: 27149100]
[63]
McCormick, Z.; Chang-Chien, G.; Marshall, B.; Huang, M.; Harden, R.N. Phantom limb pain: a systematic neuroanatomical-based review of pharmacologic treatment. Pain Med., 2014, 15(2), 292-305.
[http://dx.doi.org/10.1111/pme.12283] [PMID: 24224475]
[64]
Cruccu, G.; Nurmikko, T.J.; Ernault, E.; Riaz, F.K.; McBride, W.T.; Haanpää, M. Superiority of capsaicin 8% patch versus oral pregabalin on dynamic mechanical allodynia in patients with peripheral neuropathic pain. Eur. J. Pain, 2018, 22(4), 700-706.
[http://dx.doi.org/10.1002/ejp.1155] [PMID: 29194851]
[65]
Campbell, C.M.; Diamond, E.; Schmidt, W.K.; Kelly, M.; Allen, R.; Houghton, W.; Brady, K.L.; Campbell, J.N. A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton’s neuroma. Pain, 2016, 157(6), 1297-1304.
[http://dx.doi.org/10.1097/j.pain.0000000000000544] [PMID: 26963851]
[66]
Okada, S.; Katagiri, A.; Saito, H.; Lee, J.; Ohara, K.; Iinuma, T.; Iwata, K. Functional involvement of nucleus tractus solitarii neurons projecting to the parabrachial nucleus in trigeminal neuropathic pain. J. Oral Sci., 2019, 61(2), 370-378.
[http://dx.doi.org/10.2334/josnusd.18-0355] [PMID: 31217389]
[67]
Zhang, K.; Ramamurthy, S.; Prihoda, T.J.; Eckmann, M.S. Effect of delayed intrathecal administration of capsaicin on neuropathic pain induced by chronic constriction injury of the sciatic nerve in rats. J. Pain Res., 2014, 7, 547-554.
[PMID: 25246806]
[68]
Sałat, K.; Filipek, B. Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice. J. Zhejiang Univ. Sci. B, 2015, 16(3), 167-178.
[http://dx.doi.org/10.1631/jzus.B1400189] [PMID: 25743118]
[69]
Nakao, A.; Takahashi, Y.; Nagase, M.; Ikeda, R.; Kato, F. Role of capsaicin-sensitive C-fiber afferents in neuropathic pain-induced synaptic potentiation in the nociceptive amygdala. Mol. Pain, 2012, 8, 51.
[http://dx.doi.org/10.1186/1744-8069-8-51] [PMID: 22776418]
[70]
Pickering, G.; Lucchini, C. Topical treatment of localized neuropathic pain in the elderly. Drugs Aging, 2020, 37(2), 83-89.
[http://dx.doi.org/10.1007/s40266-019-00739-9] [PMID: 31916230]
[71]
Haanpää, M.; Treede, R.D. Capsaicin for neuropathic pain: linking traditional medicine and molecular biology. Eur. Neurol., 2012, 68(5), 264-275.
[http://dx.doi.org/10.1159/000339944] [PMID: 23037991]
[72]
Gajria, C.; Murray, J.; Birger, R.; Banarsee, R.; Bennett, D.L.; Tan, K.; Field, M.; Rice, A.S.; Majeed, A. Identification of patients with neuropathic pain using electronic primary care records. Inform. Prim. Care, 2011, 19(2), 83-90.
[PMID: 22417818]
[73]
van Seventer, R.; Feister, H.A.; Young, J.P., Jr; Stoker, M.; Versavel, M.; Rigaudy, L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr. Med. Res. Opin., 2006, 22(2), 375-384.
[http://dx.doi.org/10.1185/030079906X80404] [PMID: 16466610]
[74]
Toth, C.; Lander, J.; Wiebe, S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med., 2009, 10(5), 918-929.
[http://dx.doi.org/10.1111/j.1526-4637.2009.00655.x] [PMID: 19594844]
[75]
Attal, N. Pharmacological treatments of neuropathic pain: The latest recommendations. Rev. Neurol. (Paris), 2019, 175(1-2), 46-50.
[http://dx.doi.org/10.1016/j.neurol.2018.08.005] [PMID: 30318260]
[76]
Allegri, M.; Baron, R.; Hans, G.; Correa-Illanes, G.; Mayoral Rojals, V.; Mick, G.; Serpell, M. A pharmacological treatment algorithm for localized neuropathic pain. Curr. Med. Res. Opin., 2016, 32(2), 377-384.
[http://dx.doi.org/10.1185/03007995.2015.1129321] [PMID: 26641136]
[77]
Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpää, M.; Hansson, P.; Jensen, T.S.; Kamerman, P.R.; Lund, K.; Moore, A.; Raja, S.N.; Rice, A.S.; Rowbotham, M.; Sena, E.; Siddall, P.; Smith, B.H.; Wallace, M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol., 2015, 14(2), 162-173.
[http://dx.doi.org/10.1016/S1474-4422(14)70251-0] [PMID: 25575710]
[78]
Finnerup, N.B.; Sindrup, S.H.; Jensen, T.S. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med. Rep., 2010, 2, 52.
[http://dx.doi.org/10.3410/M2-52] [PMID: 21170362]
[79]
Dworkin, R.H.; O’Connor, A.B.; Audette, J.; Baron, R.; Gourlay, G.K.; Haanpää, M.L.; Kent, J.L.; Krane, E.J.; Lebel, A.A.; Levy, R.M.; Mackey, S.C.; Mayer, J.; Miaskowski, C.; Raja, S.N.; Rice, A.S.; Schmader, K.E.; Stacey, B.; Stanos, S.; Treede, R.D.; Turk, D.C.; Walco, G.A.; Wells, C.D. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc., 2010, 85(3)(Suppl.), S3-S14.
[http://dx.doi.org/10.4065/mcp.2009.0649] [PMID: 20194146]
[80]
Alcántara Montero, A.; Sánchez Carnerero, C.I. Eslicarbazepine acetate for neuropathic pain, headache, and cranial neuralgia: evidence and experience. Neurologia, 2019, 34(6), 386-395.
[http://dx.doi.org/10.1016/j.nrl.2016.11.009] [PMID: 28215909]
[81]
Vorobeychik, Y.; Gordin, V.; Mao, J.; Chen, L. Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs, 2011, 25(12), 1023-1034.
[http://dx.doi.org/10.2165/11596280-000000000-00000] [PMID: 22133325]
[82]
Park, H.J.; Moon, D.E. Pharmacologic management of chronic pain. Korean J. Pain, 2010, 23(2), 99-108.
[http://dx.doi.org/10.3344/kjp.2010.23.2.99] [PMID: 20556211]
[83]
Paisley, P.; Serpell, M. The role of topiceuticals in cancer pain. Curr. Opin. Support. Palliat. Care, 2017, 11(2), 93-98.
[http://dx.doi.org/10.1097/SPC.0000000000000271] [PMID: 28460372]
[84]
Pollack, C. V., Jr; Viscusi, E. R. Improving acute pain management in emergency medicine Hosp. Pract., 2015, 43(1), 36-45.
[85]
Stanos, S.P.; Galluzzi, K.E. Topical therapies in the management of chronic pain. Postgrad. Med., 2013, 125(4)(Suppl. 1), 25-33.
[http://dx.doi.org/10.1080/00325481.2013.1110567111] [PMID: 24547601]
[86]
Crawford, P.; Xu, Y. Topical capsaicin for treatment of chronic neuropathic pain in adults. Am. Fam. Physician, 2017, 96(11)
[87]
Derry, S.; Rice, A.S.; Cole, P.; Tan, T.; Moore, R.A. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2017, 1, CD007393.
[http://dx.doi.org/10.1002/14651858.CD007393.pub4] [PMID: 28085183]
[88]
Sommer, C.; Cruccu, G. Topical treatment of peripheral neuropathic pain: applying the evidence. J. Pain Symptom Manage., 2017, 53(3), 614-629.
[http://dx.doi.org/10.1016/j.jpainsymman.2016.09.015] [PMID: 28042075]
[89]
Sawynok, J. Topical analgesics for neuropathic pain in the elderly: current and future prospects. Drugs Aging, 2014, 31(12), 853-862.
[http://dx.doi.org/10.1007/s40266-014-0218-9] [PMID: 25373920]
[90]
Cobzaru, A. High-concentration capsaicin patch (qutenza) - a new step in treatment of neuropathic pain. Maedica (Buchar.), 2012, 7(1), 88-89.
[PMID: 23118828]
[91]
Chung, M.K.; Campbell, J.N. Use of capsaicin to treat pain: mechanistic and therapeutic considerations. Pharmaceuticals (Basel), 2016, 9(4), E66.
[http://dx.doi.org/10.3390/ph9040066] [PMID: 27809268]
[92]
Wagner, T.; Roth-Daniek, A.; Sell, A.; England, J.; Kern, K.U. Capsaicin 8% patch for peripheral neuropathic pain: review of treatment best practice from ‘real-world’ clinical experience. Pain Manag, 2012, 2(3), 239-250.
[http://dx.doi.org/10.2217/pmt.12.13] [PMID: 24654666]
[93]
Hutchinson, M.R.; Buijs, M.; Tuke, J.; Kwok, Y.H.; Gentgall, M.; Williams, D.; Rolan, P. Low-dose endotoxin potentiates capsaicin-induced pain in man: evidence for a pain neuroimmune connection. Brain Behav. Immun., 2013, 30, 3-11.
[http://dx.doi.org/10.1016/j.bbi.2013.03.002] [PMID: 23499731]
[94]
Moon, J.Y.; Lee, P.B.; Kim, Y.C.; Lee, S.C.; Nahm, F.S.; Choi, E. Efficacy and safety of 0.625% and 1.25% capsaicin patch in peripheral neuropathic pain: multi-center, randomized, and semi-double blind controlled study. Pain Physician, 2017, 20(2), 27-35.
[PMID: 28158151]
[95]
Zakir, H.M.; Mostafeezur, R.M.; Suzuki, A.; Hitomi, S.; Suzuki, I.; Maeda, T.; Seo, K.; Yamada, Y.; Yamamura, K.; Lev, S.; Binshtok, A.M.; Iwata, K.; Kitagawa, J. Expression of TRPV1 channels after nerve injury provides an essential delivery tool for neuropathic pain attenuation. PLoS One, 2012, 7(9)
[http://dx.doi.org/10.1371/journal.pone.0044023] [PMID: 22962595]
[96]
Burness, C.B.; McCormack, P.L. Capsaicin 8 % patch: a review in peripheral neuropathic pain. Drugs, 2016, 76(1), 123-134.
[http://dx.doi.org/10.1007/s40265-015-0520-9] [PMID: 26666418]
[97]
Üçeyler, N.; Sommer, C. High-dose capsaicin for the treatment of neuropathic pain: what we know and what we need to know. Pain Ther., 2014, 3(2), 73-84.
[http://dx.doi.org/10.1007/s40122-014-0027-1] [PMID: 25069571]
[98]
Tamburini, N.; Bollini, G.; Volta, C.A.; Cavallesco, G.; Maniscalco, P.; Spadaro, S.; Qurantotto, F.; Ragazzi, R. Capsaicin patch for persistent postoperative pain after thoracoscopic surgery, report of two cases. J. Vis. Surg., 2018, 4, 51.
[http://dx.doi.org/10.21037/jovs.2018.02.06] [PMID: 29682461]
[99]
Anand, P.; Bley, K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br. J. Anaesth., 2011, 107(4), 490-502.
[http://dx.doi.org/10.1093/bja/aer260] [PMID: 21852280]
[100]
Pickering, G.; Martin, E.; Tiberghien, F.; Delorme, C.; Mick, G. Localized neuropathic pain: an expert consensus on local treatments. Drug Des. Devel. Ther., 2017, 11, 2709-2718.
[http://dx.doi.org/10.2147/DDDT.S142630] [PMID: 29066862]
[101]
Casale, R.; Symeonidou, Z.; Bartolo, M. Topical treatments for localized neuropathic pain. Curr. Pain Headache Rep., 2017, 21(3), 15.
[http://dx.doi.org/10.1007/s11916-017-0615-y] [PMID: 28271334]
[102]
Baron, R.; Binder, A.; Attal, N.; Casale, R.; Dickenson, A.H.; Treede, R.D. Neuropathic low back pain in clinical practice. Eur. J. Pain, 2016, 20(6), 861-873.
[http://dx.doi.org/10.1002/ejp.838] [PMID: 26935254]
[103]
Giménez-Milà, M.; Videla, S.; Navarro, M.A.; Faulí, A.; Ojeda, A.; Bogdanovich, A.; Moreno, L.A.; Hernández-Cera, C.; Busquets, C. Assessment of the feasibility of high-concentration capsaicin patches in the pain unit of a tertiary hospital for a population of mixed refractory peripheral neuropathic pain syndromes in non-diabetic patients. BMC Anesthesiol., 2014, 14, 120.
[http://dx.doi.org/10.1186/1471-2253-14-120] [PMID: 25580085]
[104]
Maihöfner, C.G.; Heskamp, M.L. Treatment of peripheral neuropathic pain by topical capsaicin: impact of pre-existing pain in the QUEPP-study. Eur. J. Pain, 2014, 18(5), 671-679.
[http://dx.doi.org/10.1002/j.1532-2149.2013.00415.x] [PMID: 24259265]
[105]
Mankowski, C.; Patel, S.; Trueman, D.; Bentley, A.; Poole, C. Cost-effectiveness of capsaicin 8% patch compared with pregabalin for the treatment of patients with peripheral neuropathic pain in Scotland. PLoS One, 2016, 11(3), e0150973.
[http://dx.doi.org/10.1371/journal.pone.0150973] [PMID: 26983018]
[106]
Smith, H.; Brooks, J.R. Capsaicin-based therapies for pain control. Prog. Drug Res., 2014, 68, 129-146.
[PMID: 24941667]
[107]
Uta, D.; Yoshimura, M.; Koga, K. Chronic pain models amplify transient receptor potential vanilloid 1 (TRPV1) receptor responses in adult rat spinal dorsal horn. Neuropharmacology, 2019, 160, 107753.
[http://dx.doi.org/10.1016/j.neuropharm.2019.107753] [PMID: 31493465]
[108]
Moran, M.M.; Szallasi, A. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. Br. J. Pharmacol., 2018, 175(12), 2185-2203.
[http://dx.doi.org/10.1111/bph.14044] [PMID: 28924972]
[109]
Brederson, J.D.; Kym, P.R.; Szallasi, A. Targeting TRP channels for pain relief. Eur. J. Pharmacol., 2013, 716(1-3), 61-76.
[http://dx.doi.org/10.1016/j.ejphar.2013.03.003] [PMID: 23500195]
[110]
Claudino, R.; Nones, C.; Araya, E.; Chichorro, J. Analgesic effects of intranasal ketamine in rat models of facial pain. J. Oral Facial Pain Headache, 2018, 32(3), 238-346.
[http://dx.doi.org/10.11607/ofph.1973] [PMID: 29697717]
[111]
Shen, J.; Fox, L.E.; Cheng, J. Differential effects of peripheral versus central coadministration of QX-314 and capsaicin on neuropathic pain in rats. Anesthesiology, 2012, 117(2), 365-380.
[http://dx.doi.org/10.1097/ALN.0b013e318260de41] [PMID: 22739765]
[112]
Argoff, C.E. Topical analgesics in the management of acute and chronic pain. Mayo Clin. Proc., 2013, 88(2), 195-205.
[http://dx.doi.org/10.1016/j.mayocp.2012.11.015] [PMID: 23374622]
[113]
England, J.; Wagner, T.; Kern, K.U.; Roth-Daniek, A.; Sell, A. The capsaicin 8% patch for peripheral neuropathic pain. Br. J. Nurs., 2011, 20(15), 926-931.
[http://dx.doi.org/10.12968/bjon.2011.20.15.926] [PMID: 21841657]
[114]
Derry, S.; Lloyd, R.; Moore, R.A.; McQuay, H.J. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2009, (4)
[http://dx.doi.org/10.1002/14651858.CD007393.pub2] [PMID: 19821411]
[115]
Tenreiro Pinto, J.; Pereira, F.C.; Loureiro, M.C.; Gama, R.; Fernandes, H.L. Efficacy analysis of capsaicin 8% patch in neuropathic peripheral pain treatment. Pharmacology, 2018, 101(5-6), 290-297.
[http://dx.doi.org/10.1159/000487444] [PMID: 29587275]
[116]
Bauchy, F.; Mouraux, A.; Deumens, R.; Leerink, M.; Ulpiano Trillig, A.; le Polain de Waroux, B.; Steyaert, A.; Joëlle, Q.L.; Forget, P. Feasibility of topical applications of natural high-concentration capsaicinoid solutions in patients with peripheral neuropathic pain: a retrospective analysis. Pain Res. Manag., 2016, 2016, 9703036.
[http://dx.doi.org/10.1155/2016/9703036] [PMID: 28115879]
[117]
Haanpää, M.; Cruccu, G.; Nurmikko, T.J.; McBride, W.T.; Docu Axelarad, A.; Bosilkov, A.; Chambers, C.; Ernault, E.; Abdulahad, A.K. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur. J. Pain, 2016, 20(2), 316-328.
[http://dx.doi.org/10.1002/ejp.731] [PMID: 26581442]
[118]
Gaul, C.; Resch, S. Application of the capsaicin 8% cutaneous patch in neuropathic pain of the head and face: a case series. Cephalalgia, 2015, 35(6), 545-550.
[http://dx.doi.org/10.1177/0333102414550107] [PMID: 25217483]
[119]
Jensen, T.S.; Høye, K.; Fricová, J.; Vanelderen, P.; Ernault, E.; Siciliano, T.; Marques, S. Tolerability of the capsaicin 8% patch following pretreatment with lidocaine or tramadol in patients with peripheral neuropathic pain: a multicentre, randomized, assessor-blinded study. Eur. J. Pain, 2014, 18(9), 1240-1247.
[http://dx.doi.org/10.1002/j.1532-2149.2014.00479.x] [PMID: 24664539]
[120]
Höper, J.; Helfert, S.; Heskamp, M.L.; Maihöfner, C.G.; Baron, R. High concentration capsaicin for treatment of peripheral neuropathic pain: effect on somatosensory symptoms and identification of treatment responders. Curr. Med. Res. Opin., 2014, 30(4), 565-574.
[http://dx.doi.org/10.1185/03007995.2013.869491] [PMID: 24286590]
[121]
Knolle, E.; Zadrazil, M.; Kovacs, G.G.; Medwed, S.; Scharbert, G.; Schemper, M. Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo- controlled study. Pain, 2013, 154(12), 2729-2736.
[http://dx.doi.org/10.1016/j.pain.2013.08.001] [PMID: 23933232]
[122]
Wagner, T.; Poole, C.; Roth-Daniek, A. The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med., 2013, 14(8), 1202-1211.
[http://dx.doi.org/10.1111/pme.12143] [PMID: 23710678]
[123]
Gustorff, B.; Poole, C.; Kloimstein, H.; Hacker, N.; Likar, R. Treatment of neuropathic pain with the capsaicin 8% patch: quantitative sensory testing (QST) in a prospective observational study identifies potential predictors of response to capsaicin 8% patch treatment. Scand. J. Pain, 2013, 4(3), 138-145.
[http://dx.doi.org/10.1016/j.sjpain.2013.04.001] [PMID: 29913914]
[124]
Roberts, K.; Shenoy, R.; Anand, P. A novel human volunteer pain model using contact heat evoked potentials (CHEP) following topical skin application of transient receptor potential agonists capsaicin, menthol and cinnamaldehyde. J. Clin. Neurosci., 2011, 18(7), 926-932.
[http://dx.doi.org/10.1016/j.jocn.2010.11.015] [PMID: 21550252]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 3
Year: 2021
Published on: 16 November, 2020
Page: [198 - 207]
Pages: 10
DOI: 10.2174/1389200221999201116143701
Price: $65

Article Metrics

PDF: 44
HTML: 2